Nanoparticle-based drug delivery systems: What can they really do in vivo? [version 1; referees: 3 approved]
In the past few decades, there has been explosive growth in the construction of nanoparticle-based drug delivery systems (NDDSs), namely nanomedicines, owing to their unique properties compared with traditional drug formulations. However, because of a variety of challenges, few nanomedicines are on...
Main Authors: | Yi-Feng Wang, Lu Liu, Xue Xue, Xing-Jie Liang |
---|---|
Format: | Article |
Language: | English |
Published: |
F1000 Research Ltd
2017-05-01
|
Series: | F1000Research |
Subjects: | |
Online Access: | https://f1000research.com/articles/6-681/v1 |
Similar Items
-
High quality, small molecule-activity datasets for kinase research [version 1; referees: 2 approved]
by: Rajan Sharma, et al.
Published: (2016-06-01) -
High quality, small molecule-activity datasets for kinase research [version 3; referees: 2 approved]
by: Rajan Sharma, et al.
Published: (2016-10-01) -
High quality, small molecule-activity datasets for kinase research [version 2; referees: 2 approved]
by: Rajan Sharma, et al.
Published: (2016-07-01) -
Recent advances in (therapeutic protein) drug development [version 1; referees: 2 approved]
by: H.A. Daniel Lagassé, et al.
Published: (2017-02-01) -
DNA nanochannels [version 1; referees: 2 approved]
by: Dianming Wang, et al.
Published: (2017-04-01)